Single-port symphonX: game changer in minimally invasive surgery

20 January 2017 (Last Updated January 20th, 2017 06:10)

Fortimex Surgical has received Conformité Européenne (CE) approval for the symphonX surgical platform. How will this change minimally invasive surgery?

Single-port symphonX: game changer in minimally invasive surgery

In October 2016, Fortimex Surgical announced that it had received Conformité Européenne (CE) approval for the symphonX surgical platform, the first single-port surgical device on the market. In the same month, Fortimex Surgical announced the commercial launch of symphonX in the US, and is expected to commercially launch in the EU in early 2017. In addition to symphonX being the first device of its kind, it is also the latest device in the growing minimally invasive surgery trend.

SymphonX has four access lumens that allow the simultaneous use of a laparoscope, suction, and two other instruments. This allows for surgeries to be performed through a single port rather than requiring several incisions. To date, the symphonX surgical platform has been used to perform various general and gynecological surgeries such as a hernia repair, gallbladder removal, and tubal sterilization.

Minimally invasive (or laparoscopic) surgeries have become a gold standard for many surgical procedures. The advantages provided to the patient through standard minimally invasive procedures, such as fewer post-operative complications, can only be further advanced by decreasing the number of necessary incisions to a single site. The single-port symphonX system reduces post-operative pain and results in fewer port-site complications, leading to a faster recovery and overall better surgical outcomes.

Prior to the launch of the symphonX surgical platform, surgical robots were the only option for single port or single-site instrumentation. The fast growth of the surgical robotic systems market, with an expected Compound Annual Growth Rate (CAGR) in the double digits over the next five years, supports a promising growth for other novel minimally invasive surgical instruments, such as the symphonX platform.

While surgical robotic systems are highly precise devices that are able to be operated remotely, their high capital cost does threaten to limit their use to larger institutes. Surgical platforms such as the symphonX platform may make single-site surgeries more accessible to smaller institutions, and therefore allow more patients to receive state-of-the-art care.